By Adriano Marchese
Lexeo Therapeutics said Wednesday that it received positive data for its Alzheimer's disease treatment, which suggests that higher doses improved results.
The clinical-stage genetic medicine company said the results are from the phase 1/2 study for its LX1001 drug.
The treatment involves around APOE genes and AD-associated tau biomarkers, two important factors in Alzheimer's disease.
"APOE2 is associated with a significantly lower risk of Alzheimer's onset and slower disease progression," the company said.
The study's primary objective was to assess safety and tolerability of the treatment. Secondary outcomes include APOE2 protein expression and changes in the biomarkers.
"The study also resulted in notable reductions in tau biomarkers, which suggest a possible effect on Alzheimer's disease pathology," said Kim Johnson, division chief for memory disorders at the neurology department at Duke University School of Medicine and a principal investigator in the study.
The data were presented at the Clinical Trials on Alzheimer's Disease conference in Madrid, Spain.
Lexeo said it contacted the Food and Drug Administration with the data it has collected. It expects to provide regulatory updates and any new development plans for the drug in 2025.
Write to Adriano Marchese at adriano.marchese@wsj.com
(END) Dow Jones Newswires
October 30, 2024 07:26 ET (11:26 GMT)
Copyright (c) 2024 Dow Jones & Company, Inc.
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。